{"id":673648,"date":"2023-10-24T18:38:01","date_gmt":"2023-10-24T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=673648"},"modified":"2023-10-24T18:38:01","modified_gmt":"2023-10-24T18:38:01","slug":"metastatic-urothelial-carcinoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pharmamar-ectin-exelixis-merck-seagen","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-urothelial-carcinoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pharmamar-ectin-exelixis-merck-seagen_673648.html","title":{"rendered":"Metastatic Urothelial Carcinoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | PharmaMar, Ectin, Exelixis, Merck, Seagen"},"content":{"rendered":"<div style=\"float:right; width:250px;\" class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Metastatic Urothelial Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Metastatic Urothelial Carcinoma Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Metastatic Urothelial Carcinoma Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Metastatic Urothelial Carcinoma Pipeline report embraces in-depth commercial, regulatory, and Metastatic Urothelial Carcinoma clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Metastatic Urothelial Carcinoma drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Metastatic Urothelial Carcinoma Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for Metastatic Urothelial Carcinoma treatment and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different Metastatic Urothelial Carcinoma therapies segmented into early-stage, mid-stage, and late-stage clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the major Metastatic Urothelial Carcinoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the Metastatic Urothelial Carcinoma drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Metastatic Urothelial Carcinoma therapeutic market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/2643eb43a39f8b7c97daa54bafde91cc.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Urothelial Carcinoma Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Urothelial Carcinoma, also known as transitional cell carcinoma (TCC), is characterized by cancer beginning in the urothelial cells lining the bladder, it is one of the most common forms of bladder cancer (BC). Treatment for metastatic form of Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic Urothelial Carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancements in the treatment of new immunotherapies, more alternatives are available.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Chemotherapy majorly forms the first line of treatment, mainly comprising platinum-based products. Cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The commonly used cisplatin regimens include MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine and cisplatin). Cisplatin is followed by Carboplatin for therapeutic regimens, such as M-CAVI (methotrexate, carboplatin, and vinblastine). A few nonplatinum regimens include gemcitabine with a taxane (either paclitaxel or docetaxel) rather than platinum. Single-agent chemotherapy also holds importance in the treatment routine, including Gemcitabine, Vinflunine, and Ifosfamide.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The major class of treatment also comprises Immunotherapy, which helps the patient&rsquo;s own immune system to recognize and destroy cancer cells. Developments in this domain have led to the development of immune checkpoint inhibitors (ICIs) targeting the programmed death (PD-1\/PDL-1) pathway. Immunotherapy is used in platinum ineligible or refractory cases. The market holds Atezolizumab (Tecentriq), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Durvalumab (Imfinzi), and Avelumab (Bavencio) as approved products targeting PD-1\/PDL-1 pathway.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">There are approx. 40+ key companies developing therapies for Metastatic Urothelial Carcinoma. Currently, PharmaMar is leading the therapeutics market with its Metastatic Urothelial Carcinoma drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Metastatic Urothelial Carcinoma Companies Actively Working in the Therapeutic Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">PharmaMar<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ectin Research AG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Exelixis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lilly and Company<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck Sharp &amp; Dohme LLC<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Astellas Pharma Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Seagen Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Shanghai Miracogen Inc.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Advaxis, Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emerging and Marketed Metastatic Urothelial Carcinoma Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">MFA 370: Ectin Research AG<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">XL 092: Exelixis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lurbinectedin: PharmaMar<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ramucirumab: Eli Lilly<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Infigratinib: QED Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rogaratinib: Bayer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pemigatinib: Incyte Corporation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sacituzumab govitecan: Immunomedics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NKTR-214: Nektar Therapeutics\/Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RX-3117: Rexahn Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Metastatic Urothelial Carcinoma Companies Working in the Market @&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Metastatic Urothelial Carcinoma Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers the emerging products under different phases of clinical development like &#8211;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage products (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued and inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Metastatic Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intra-articular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intraocular<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intrathecal<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ophthalmic<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Parenteral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Topical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oligonucleotide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Peptide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Metastatic Urothelial Carcinoma Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Metastatic Urothelial Carcinoma Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Metastatic Urothelial Carcinoma &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Metastatic Urothelial Carcinoma Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Metastatic Urothelial Carcinoma Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Metastatic Urothelial Carcinoma Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Metastatic Urothelial Carcinoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Metastatic Urothelial Carcinoma Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Major Metastatic Urothelial Carcinoma Companies in the Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Metastatic Urothelial Carcinoma Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Metastatic Urothelial Carcinoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Metastatic Urothelial Carcinoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Metastatic Urothelial Carcinoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/metastatic-urothelial-carcinoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/nicotine-addiction-market\">Nicotine Addiction Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Nicotine Addiction Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nicotine Addiction market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Nicotine Addiction market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-urothelial-carcinoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pharmamar-ectin-exelixis-merck-seagen\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/medical-devices\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/medical-devices<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/medical-devices\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-urothelial-carcinoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pharmamar-ectin-exelixis-merck-seagen\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Metastatic Urothelial Carcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-urothelial-carcinoma-pipeline-analysis-2023-covering-clinical-trials-emerging-therapies-fda-ema-and-pmda-approvals-competitive-landscape-pharmamar-ectin-exelixis-merck-seagen_673648.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,417,406,404],"tags":[],"class_list":["post-673648","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/673648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=673648"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/673648\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=673648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=673648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=673648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}